Arvinas (ARVN) stock
Follow ARVN's trial news. Pro members can get an alert when Arvinas files news, and see its trials, share raises, and its CEO's filings.
What's next for ARVN, and how long its cash lasts
From Arvinas’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 11 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Nov 7, 2023)
- At-the-market share sales program (S-3ASR, filed Nov 7, 2023)
Insiders
CFO Andrew Saik sold 5,696 shares on Jun 24, under a planned sale. 18 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why ARVN lags the market
Arvinas returned -91% over five years to the S&P 500's +88%; free cash flow went from -$96.1M to -$275.7M.
2 drivers, the timeline, and the peer table, for Pro members
Why ARVN scores -2
PoorTransition, 0 of 14 checks firingWhat the Quality Score means
- −3Long-term trend below a falling 200-day average, down over one year, down over two years
- +2Profit Made $9M over the last four quarters, after a loss of $73M the four before, from the SEC filings
- Cash flow subtracts
What's next
Expected to report Wed Nov 4, before the open
After its last 4 reports it closed +2.9% on average, higher 3 of 4 times.
What would turn ARVN's score around: 6 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
Nothing is firing on ARVN right now
One per group is shown here.
Also on the chart
- RSI 1432.1
- MACD (12, 26, 9)Below signal
- 50-day average$8.63
- 200-day average$10.16
- ADX 1420.3
- Support$6.97
- Resistance$8.40
- Bollinger Bands (20, 2)Inside
- Volume0.9x
How ARVN ranks in Pharma
ARVN is #71 of 89 by Quality Score. The top three are shown with their scores, and more by name.
ABBV5/1416
GMAB6/1413
PFE5/1413
ANROOpen for its score
ARDXOpen for its score
ARWROpen for its score
AZNOpen for its score
ARVN0/14-2
When does ARVN report earnings, and what happens after?
Expected to report Wed Nov 4, before the open (in 33 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 4, 2026Before open | Before open | +3.4% | +11.7% | +11.5% |
| May 12, 2026Before open | Before open | +1.8% | -0.9% | -9.1% |
| Feb 24, 2026Before open | Before open | -7.9% | +0.6% | +8.9% |
| Nov 5, 2025Before open | Before open | -1.1% | +0.3% | +17.5% |
About Arvinas
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of ARVN's score, with the points and the reason
- All 14 checks on ARVN and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ARVN
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.